NCT02047604: A trial that was reported late by Bausch Health Americas, Inc.
This trial has reported, although it was 41 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02047604 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s). |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 31, 2013 |
| Completion date | Feb. 23, 2017 |
| Required reporting date | Feb. 23, 2018, midnight |
| Actual reporting date | April 5, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 41 |